Review of key trends in the development of new depression drugs across the seven major markets. Also includes detailed analyses of clinical trial design, target product profile, innovative early-stage projects, and future treatment developments.
Description
INTRODUCTION
Several drugs have progressed through the pipeline for depression in recent years, including Pristiq (desvenlafaxine; Pfizer), Oleptro (trazodone extended release; Labopharm), and Viibryd (Forest) in the US, and Valdoxan (agomelatine; Servier/Novartis) in the EU. Despite the heightened competition within the marketplace, an abundance of drugs remain in the pipeline.
FEATURES AND BENEFITS
Understand key dynamics in the R&D pipeline for new depression therapies
Benchmark novel and existing therapies using the target product profile identified by Datamonitor
Support R&D decision making by evaluating antidepressant clinical trial designs that have set a precedent
Evaluate the most promising new pharmacological targets in early-stage development
Access Datamonitor's prediction of how the treatment landscape may change in the next 20 years
HIGHLIGHTS
There are 46 separate programs across all stages of clinical development for depression, down from 66 in 2007 with a notably high attrition of early-stage projects. Reasons for this include promising new targets failing to yield an effective antidepressant, and big players such as GlaxoSmithKline switching its research focus.
Although depleted, the early-stage pipeline still has the potential to change current treatment algorithms, which are dominated by monoamine reuptake inhibitors. Popular approaches include glutamate and neuropeptide receptor modulation. Datamonitor sees the future of treatment in depression as the specific targeting of treatment-resistant patients.
Clinical trial design in depression is largely standardized. Although not required, head-to-head trials may allow for a more favorable label and explicit marketing claims. Datamonitor believes that future trials will be designed for regulatory approval in patients with treatment-resistant depression, or for use as an add-on to existing therapies.
YOUR KEY QUESTIONS ANSWERED
What are the key trends in the depression pipeline?
What is the clinical gold standard and how do new candidates have to compare to this to successfully penetrate the market?
How will new antidepressant treatments evolve in the next 20 years?
Table of Contents
TOC
OVERVIEW
Catalyst
Summary
EXECUTIVE SUMMARY
Strategic scoping and focus
Update details: January 2012
Datamonitor key findings
Related reports
CLINICAL PIPELINE OVERVIEW
Overview of the depression pipeline
Datamonitor has identified 46 separate programs in clinical development
Emerging features of the depression pipeline
Changes in pipeline dynamics
Companies involved in the depression pipeline
Discontinued pipeline drugs in depression
54 distinct depression projects have been discontinued since 2010
The vast majority of discontinuations happen either during preclinical testing or Phase II studies
Neuropeptide modulators and monoamine reuptake inhibitors head the list of discontinued projects
TARGET PRODUCT PROFILE
Comparator therapies
Lexapro (escitalopram; Forest/Lundbeck)
Target product profile versus current level of attainment
CLINICAL TRIAL DESIGN IN DEPRESSION
Clinical trials
Commonly used clinical trial endpoints for depression
Typical trial design
Trial length is commonly standardized to a duration of just 8 weeks
Comparator trials can provide a compelling argument for using one drug ahead of another
Table: Most promising innovative therapeutic approaches in depression, January 2012
FIGURES
Figure: Depression clinical pipeline, by developmental stage, January 2012
Figure: Depression clinical pipeline, by mode of action, January 2012
Figure: Products in clinical development for depression, 2007, 2011, and 2012
Figure: Modes of action in the depression pipeline, 2007, 2011, and 2012
Figure: Depression pipeline, by developmental stage and company type, January 2012
Figure: Big Pharma's involvement in the depression pipeline, January 2012
Figure: Discontinued drugs formerly in development for depression, by developmental stage, 2010-12
Figure: Modes of action of discontinued pipeline drugs and active pipeline drugs in depression, 2010-12
Figure: Head-to-head clinical trial of Lexapro (escitalopram; Forest/Lundbeck) versus Celexa (citalopram; Forest/Lundbeck)
Figure: Potential timeline for future depression therapies
Figure: Proportion of patients that display treatment-resistant depression (%) in the seven major markets, 2010
Figure: BRITE-MD study of the Antidepressant Treatment Response Index as a functional biomarker for depression
R&D Trends: Depression - Clinical attrition driven by mature market conditions published by Datamonitor in January 25, 2012. This report consists of Pages: 53 and the price starts from US $ 3800.
The contents of this page may be different from the latest version. Please contact us for details.
